Skip to main content
ACOG logo

ACOG · Alpha Cognition Inc. · Webcasts, Transcripts & Audio

Track ACOG — free
$8.97 -0.13 (-1.43%) At close · Oct 5
Market Cap
$186.20M
Shares
21.78M
Volume · Oct 5 52.6K Avg daily vol (3M) 125K

Alpha Cognition Inc. Webcasts

Earnings calls, investor updates, investor days and conferences for Alpha Cognition Inc. (ACOG), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Earnings call
FY26 · Q1
2026-03-31
Alpha Cognition Inc. (ACOG) Q1 2026 Earnings Call Transcript
Confident tone ZUNVEYL Commercial Launch Clinical / Real-World Evidence Programs Prescriber & Sales Force Growth
Revenue
$3.53M
▲ 20.7% YoY
Diluted EPS
$-0.32
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-03-26
Alpha Cognition Inc. (ACOG) Q4 2025 Earnings Call Transcript
Confident tone ZUNVEYL commercial launch and revenue growth Real-world evidence studies (BEACON, CONVERGE, RESOLVE) Long-term care adoption and prescriber expansion
Revenue
$2.79M*
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-09-30
Alpha Cognition Inc. (ACOG) Q3 2025 Earnings Call Transcript
Confident tone ZUNVEYL commercial launch metrics International expansion via CMS Pharma in China Pricing and gross-to-net
Revenue
$2.84M
▼ 97.2% YoY
Diluted EPS
$-0.30
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-06-30
Alpha Cognition Inc. (ACOG) Q2 2025 Earnings Call Transcript
Confident tone ZUNVEYL commercial launch Sublingual formulation R&D Healthcare professional engagement
Revenue
$1.66M
▼ 98.3% YoY
Diluted EPS
$-0.82
Gross margin
87.7%
Rev · 4q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-03-31
Alpha Cognition Inc. (ACOG) Q1 2025 Earnings Call Transcript
Confident tone ZUNVEYL commercial launch Medicare reimbursement and access Intellectual property and patents
Revenue
$2.93M
Diluted EPS
$-0.11
Rev · 3q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Showing 1–5 of 5 webcasts
Key facts CIK 1655923 CUSIP 02074J501 Visit website Investor relations